SCHEMBL3013953

SCHEMBL3013953

COc1ccc(Br)cc1S(=O)(=O)C1CCN(c2nc(Cc3c(C)cc(C)cc3C)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.39
ALOX15 P16050 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
GLA P06280 1/20 0.36
DRD2 P14416 5/20 0.36
DRD4 P21917 5/20 0.36
DRD3 P35462 5/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
PPARG P37231 1/20 0.35
GFER P55789 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015964 0.93 GAA (0.39) GAAALOX15L3MBTL1SMN1; SMN2GLA
SCHEMBL3000603 0.91 GAA (0.39) GAAALOX15L3MBTL1SMN1; SMN2GLA
SCHEMBL3006747 0.91 L3MBTL1 (0.46) GAAL3MBTL1SMN1; SMN2ALDH1A1LMNA
SCHEMBL3007436 0.90 MAPK1 (0.39) L3MBTL1SMN1; SMN2DRD2ALDH1A1LMNA
SCHEMBL3019945 0.89 GAA (0.39) GAAALOX15SMN1; SMN2GLADRD2
SCHEMBL3012540 0.88 GAA (0.38) GAAALOX15SMN1; SMN2GLADRD2
SCHEMBL3006097 0.87 GAA (0.38) GAAALOX15SMN1; SMN2GLADRD2
SCHEMBL3017679 0.87 DRD2 (0.39) GAAALOX15SMN1; SMN2DRD2DRD4
SCHEMBL3016703 0.87 DRD2 (0.39) GAAALOX15SMN1; SMN2DRD2DRD4
SCHEMBL3011768 0.86 HCRTR1 (0.36) SMN1; SMN2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GAA 110/4885ALOX15 2079/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.